Form 4: Myriad Genetics Director Lee Nisley Newcomer Reports Acquisition and Disposal of Common Stock

Director Lee Nisley Newcomer reports acquiring and disposing of Myriad Genetics common stock, including restricted stock units, in a recent transaction.

Summary

• On June 6, 2024, Lee Nisley Newcomer, a director of Myriad Genetics Inc., reported a transaction involving the company's common stock.
• Newcomer acquired 15,695 shares of common stock at $0.
• Newcomer disposed of 82,345 shares of common stock.
• Following the reported transactions, Newcomer beneficially owns 82,345 shares of Myriad Genetics Inc.
• The acquisition involved restricted stock units granted under the company's 2017 Employee, Director and Consultant Equity Incentive Plan, which vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing is a standard disclosure of insider transactions. The acquisition of shares through restricted stock units is a positive sign, but the disposal of a larger number of shares tempers the overall sentiment.

Positives

• The acquisition of restricted stock units indicates continued alignment of the director's interests with the company's performance.

Negatives

• The disposal of 82,345 shares could be interpreted negatively by some investors, although the reason for the disposal is not specified.

Risks

• The Form 4 filing itself doesn't inherently indicate risks, but market perception of insider transactions can influence stock price.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge sentiment and potential future actions by key personnel.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in the biotech industry, as it provides insights into management's confidence in the company's prospects.
• Comparing the volume and frequency of insider transactions at Myriad Genetics to those of its peers, such as Exact Sciences or Illumina, can offer a broader perspective on the company's internal dynamics.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price in the short term.
• Employees holding similar equity incentives may be interested in the vesting terms and implications of the reported transactions.

Key Dates